CN101678120A - 前药及其制备和使用方法 - Google Patents
前药及其制备和使用方法 Download PDFInfo
- Publication number
- CN101678120A CN101678120A CN200780050871A CN200780050871A CN101678120A CN 101678120 A CN101678120 A CN 101678120A CN 200780050871 A CN200780050871 A CN 200780050871A CN 200780050871 A CN200780050871 A CN 200780050871A CN 101678120 A CN101678120 A CN 101678120A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrogen
- prodrug
- prodrug moiety
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87351906P | 2006-12-05 | 2006-12-05 | |
| US60/873,519 | 2006-12-05 | ||
| PCT/US2007/024984 WO2008070149A2 (en) | 2006-12-05 | 2007-12-05 | Prodrugs and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101678120A true CN101678120A (zh) | 2010-03-24 |
Family
ID=39361296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780050871A Pending CN101678120A (zh) | 2006-12-05 | 2007-12-05 | 前药及其制备和使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080318905A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2121029A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010511717A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090086627A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101678120A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007328007A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0719937A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2671737A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006007A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20092527L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2009125597A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008070149A2 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019086017A1 (en) * | 2017-11-03 | 2019-05-09 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
| CN114380859A (zh) * | 2020-10-22 | 2022-04-22 | 威智医药有限公司 | 磷酸二苄酯及焦磷酸四苄酯的制备方法 |
| WO2024061250A1 (zh) * | 2022-09-23 | 2024-03-28 | 合肥瀚微生物科技有限公司 | 一种抑郁症诊断的生物标记物及其应用 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| CN101622263B (zh) * | 2007-03-06 | 2013-05-29 | 卫材R&D管理有限公司 | 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| JP5757864B2 (ja) * | 2008-05-20 | 2015-08-05 | ニューロジェシックス, インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| AU2009249071A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
| AU2009249069A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Carbonate prodrugs and methods of using the same |
| BRPI0917212A2 (pt) | 2008-07-28 | 2015-11-10 | Pfizer | compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos |
| US20100076198A1 (en) * | 2008-09-19 | 2010-03-25 | Mallinckrodt Inc. | Crystalline forms of Fentanyl Alkaloid |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
| PT2445502T (pt) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| KR20180069934A (ko) * | 2011-07-28 | 2018-06-25 | 켐팜 인코포레이티드 | 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법 |
| EP2758133A4 (en) | 2011-09-22 | 2015-05-27 | Acorda Therapeutics Inc | ACETAMINOPHONE CONJUGATES, COMPOSITIONS AND METHOD OF USE THEREOF |
| WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| EP2986294A4 (en) * | 2013-04-17 | 2016-11-16 | Biopharma Works | PROCESS FOR PAIN TREATMENT |
| EP2986295A4 (en) | 2013-04-17 | 2016-11-09 | Biopharma Works | PROCESS FOR PAIN TREATMENT |
| US20160244459A1 (en) | 2013-05-24 | 2016-08-25 | Rhodes Technologies | Opioid ketal compounds and uses thereof |
| WO2015082932A1 (en) | 2013-12-05 | 2015-06-11 | The University Of Bath | Novel opioid compounds and their uses |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| WO2016181218A1 (en) | 2015-05-13 | 2016-11-17 | Yoram Sela | Stimulant abuse-deterrent compositions |
| ES2957234T3 (es) * | 2016-03-24 | 2024-01-15 | Medrx Co Ltd | Preparación de parche con características de prevención del uso incorrecto de sustancias |
| CA3091826A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
| WO2020077038A1 (en) * | 2018-10-13 | 2020-04-16 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of cgrp antagonists |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| US20220213099A1 (en) * | 2019-05-07 | 2022-07-07 | Bristol-Myers Squibb Company | Prodrug compounds |
| FI130262B (en) * | 2019-08-30 | 2023-05-17 | Medicortex Finland Oy | Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases |
| WO2021065898A1 (ja) * | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | アゼパン誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
| TR200001942T2 (tr) * | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| AU754965B2 (en) * | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| US6703398B2 (en) * | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
| MXPA05009757A (es) * | 2003-03-13 | 2005-12-05 | Controlled Chemicals Inc | Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida. |
| ES2653568T3 (es) * | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
-
2007
- 2007-12-05 EP EP07862579A patent/EP2121029A2/en not_active Withdrawn
- 2007-12-05 MX MX2009006007A patent/MX2009006007A/es not_active Application Discontinuation
- 2007-12-05 AU AU2007328007A patent/AU2007328007A1/en not_active Abandoned
- 2007-12-05 RU RU2009125597/04A patent/RU2009125597A/ru not_active Application Discontinuation
- 2007-12-05 US US11/999,660 patent/US20080318905A1/en not_active Abandoned
- 2007-12-05 CN CN200780050871A patent/CN101678120A/zh active Pending
- 2007-12-05 BR BRPI0719937-6A2A patent/BRPI0719937A2/pt not_active IP Right Cessation
- 2007-12-05 WO PCT/US2007/024984 patent/WO2008070149A2/en not_active Ceased
- 2007-12-05 JP JP2009540292A patent/JP2010511717A/ja active Pending
- 2007-12-05 CA CA002671737A patent/CA2671737A1/en not_active Abandoned
- 2007-12-05 KR KR1020097013918A patent/KR20090086627A/ko not_active Withdrawn
-
2009
- 2009-07-03 NO NO20092527A patent/NO20092527L/no not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019086017A1 (en) * | 2017-11-03 | 2019-05-09 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
| CN114380859A (zh) * | 2020-10-22 | 2022-04-22 | 威智医药有限公司 | 磷酸二苄酯及焦磷酸四苄酯的制备方法 |
| CN114380859B (zh) * | 2020-10-22 | 2024-11-01 | 威智医药股份有限公司 | 磷酸二苄酯及焦磷酸四苄酯的制备方法 |
| WO2024061250A1 (zh) * | 2022-09-23 | 2024-03-28 | 合肥瀚微生物科技有限公司 | 一种抑郁症诊断的生物标记物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080318905A1 (en) | 2008-12-25 |
| WO2008070149A3 (en) | 2009-12-10 |
| KR20090086627A (ko) | 2009-08-13 |
| EP2121029A2 (en) | 2009-11-25 |
| WO2008070149A2 (en) | 2008-06-12 |
| RU2009125597A (ru) | 2011-01-20 |
| AU2007328007A1 (en) | 2008-06-12 |
| JP2010511717A (ja) | 2010-04-15 |
| MX2009006007A (es) | 2009-07-17 |
| BRPI0719937A2 (pt) | 2014-03-11 |
| NO20092527L (no) | 2009-09-04 |
| CA2671737A1 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080318905A1 (en) | Prodrugs and methods of making and using the same | |
| US8362007B1 (en) | Substituted noribogaine | |
| AU681190B2 (en) | 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins | |
| US9586954B2 (en) | N-substituted noribogaine prodrugs | |
| AU2021215274B2 (en) | Targeted drug rescue with novel compositions, combinations, and methods thereof | |
| CN113227051B (zh) | 用于视网膜疾病的化合物 | |
| EP3312183B1 (en) | Deuterated morphine derivatives for use in analgesia | |
| JP2013523599A (ja) | 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途 | |
| JPH01294663A (ja) | 脳を標的とする薬剤供給用のレドックス系 | |
| US12492203B2 (en) | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions | |
| CN101208294A (zh) | Trpv1激动剂化合物以及制备和使用它们的方法 | |
| JP2025517349A (ja) | ピペリジニル-メチル-プリンアミンd-酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用 | |
| US20040176270A1 (en) | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | |
| JP2008526846A (ja) | 鎮痛性結合体 | |
| EP3464400B1 (en) | Polymer linkers and their uses | |
| CN101454309A (zh) | 焦谷氨酸衍生物的合成和用途 | |
| TWI924207B (zh) | 從生物活性化合物的偶聯物的選擇性藥物釋放 | |
| CN104744480A (zh) | 7-氮鎓双环[2.2.1]庚烷衍生物、其制备方法、及其制可药用途 | |
| HK1142543A (en) | Prodrugs and methods of making and using the same | |
| WO2015112168A2 (en) | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier | |
| JP4355144B2 (ja) | 新規含窒素環状化合物 | |
| CN105732651A (zh) | 一种小分子肺靶向药物 | |
| EP4577245A1 (en) | Dendrimer compositions for targeted delivery of psychedelic therapeutics | |
| JP2002515914A (ja) | 新規へテロ環式化合物 | |
| JP2026513350A (ja) | カンプトテシン誘導体の抗体-薬物コンジュゲートおよびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142543 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100324 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1142543 Country of ref document: HK |